MERTK and synucleinopathy: Lack of MerTK upregulation accompanying α-syn accumulation in the human brain and genetic associations between rare MERTK variants and Parkinson’s disease suggest MerTK as a potential therapeutic target to enhance α-syn fibril clearance by microglia in synucleinopathies.